FCF Fox Company Finance GmbH is delighted to publish the brand new “FCF Biotech Enterprise Capital Monitor – USA 12/2023”.
The Monitor is a month-to-month printed overview of enterprise capital developments within the US-Biotech sector.
As of the top of December 2023, we determine the next present VC developments within the US-Biotech sector:
- In 2023, general Biotech funding within the USA has reached USD 23,607m
- In comparison with December 2022 the financing quantity decreased by roughly 26% (31,894m vs. 23,607m)
- The highest 5 offers exceed USD 273m every, the biggest transaction amounted to USD 401m with ElevateBio
- Bicara Therapeutics has the best transaction Quantity of USD 165m in December, adopted by Lyndra Therapeutics USD 123m and Tome Biosciences USD 118m
- ARCH Enterprise Companions (USA) is main the High 5 Buyers (by deal quantity), adopted by RA Capital Administration (USA) and OrbiMed (USA)
- As a sign oncology data the best funding exercise
To entry the total report, please click on right here.
By Mathias Klozenbücher und Johannes Hyperlink.